Sigyn Therapeutics, Inc. (SIGY) stock: key figures, P/E, revenue and dividend
Health Care · United States
Sigyn Therapeutics, Inc. financials
| Fiscal year | 2024 |
|---|---|
| Operating income | -2.52 m USD |
| EBIT | -3.34 m USD |
| Net income | -3.34 m USD |
| Diluted EPS – continuing operations | -2.51 USD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Sigyn Therapeutics, Inc.
Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats. The company is also involved in the evaluation of Sigyn therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the performance of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.
More stocks
- TRAFALGAR INTERNATIONAL, INC. (GCAN)
- CNBX Pharmaceuticals Inc. (CNBX)
- Nauticus Robotics, Inc. (KITT)
- ProPhase Labs, Inc. (PRPH)
- Hongchang International Co., Ltd (HCIL)
- Digital Brands Group, Inc. (DBGI)
- First Choice Healthcare Solutions, Inc. (FCHS)
- Data443 Risk Mitigation, Inc. (ATDS)
- MEDIGENE N (MDG1.SG) (MDG1.SG)
- Petros Pharmaceuticals, Inc. (PTPI)
- Winvest Group Ltd (WNLV)
- Kuber Resources Corp (KUBR)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.